Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov;146(5):949-959.
doi: 10.1016/j.jaci.2020.09.016. Epub 2020 Sep 29.

Highways to hell: Mechanism-based management of cytokine storm syndromes

Affiliations
Review

Highways to hell: Mechanism-based management of cytokine storm syndromes

Scott W Canna et al. J Allergy Clin Immunol. 2020 Nov.

Abstract

Since the first textbook devoted to cytokine storm syndromes (CSSs) was published in 2019, the world has changed dramatically and the term's visibility has broadened. Herein, we define CSSs broadly to include life/organ-threatening systemic inflammation and immunopathology regardless of the context in which it occurs, recognizing that the indistinct borders of such a definition limit its utility. Nevertheless, we are focused on the pathomechanisms leading to CSSs, including impairment of granule-mediated cytotoxicity, specific viral infections, excess IL-18, and chimeric antigen receptor T-cell therapy. These mechanisms are often reflected in distinct clinical features, functional tests, and/or biomarker assessments. Moreover, these mechanisms often indicate specific, definitive treatments. This mechanism-focused organization is vital to both advancing the field and understanding the complexities in individual patients. However, increasing evidence suggests that these mechanisms interact and overlap. Likewise, the utility of a broad term such as "cytokine storm" is that it reflects a convergence on a systemic inflammatory phenotype that, regardless of cause or context, may be amenable to "inflammo-stabilization." CSS research must improve our appreciation of its various mechanisms and their interactions and treatments, but it must also identify the signs and interventions that may broadly prevent CSS-induced immunopathology.

Keywords: Cytokine storm; cytokine release syndrome; hemophagocytic lymphohistiocytosis; macrophage activation syndrome.

PubMed Disclaimer

Figures

Fig 1
Fig 1
The merging mechanisms that promote cytokine storm. Genetic impairment of cellular cytotoxic (A), excess of IL-18 (B), Iatrogenic T-cell hyperactivation via CAR T cells and BiTE antibodies (C), and specific infections (particularly EBV and possibly SARS-CoV2, D) converge on T- and NK-cell hyperactivation and production of lymphokines such as IFN-γ. This lymphokine surge acts on myeloid cells to promote histiocytosis, cytokine storm, and life-threatening systemic immunopathology. BiTE, Bispecific T-cell engaging.
Fig 2
Fig 2
Classification of genetic defects commonly associated with CSSs shows substantial mechanistic overlap. HPS, Hermansky-Pudlak syndrome; LPI, lysinuric protein intolerance; XMEN, X-linked immunodeficiency with magnesium defect, EBV infection, and neoplasia. Created with biorender.com.

References

    1. Henter J.I., Horne A., Arico M., Egeler R.M., Filipovich A.H., Imashuku S. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–131. - PubMed
    1. Zhang K., Jordan M.B., Marsh R.A., Johnson J.A., Kissell D., Meller J. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood. 2011;118:5794–5798. - PMC - PubMed
    1. Marsh R.A., Madden L., Kitchen B.J., Mody R., McClimon B., Jordan M.B. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood. 2010;116:1079–1082. - PMC - PubMed
    1. Pachlopnik Schmid J., Canioni D., Moshous D., Touzot F., Mahlaoui N., Hauck F. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency) Blood. 2011;117:1522–1529. - PubMed
    1. Wada T., Kanegane H., Ohta K., Katoh F., Imamura T., Nakazawa Y. Sustained elevation of serum interleukin-18 and its association with hemophagocytic lymphohistiocytosis in XIAP deficiency. Cytokine. 2014;65:74–78. - PubMed

Publication types

MeSH terms